HomeCompareAWLIF vs ABBV

AWLIF vs ABBV: Dividend Comparison 2026

AWLIF yields 487.80% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AWLIF wins by $50753.79M in total portfolio value
10 years
AWLIF
AWLIF
● Live price
487.80%
Share price
$0.41
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$50753.89M
Annual income
$36,168,404,531.85
Full AWLIF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AWLIF vs ABBV

📍 AWLIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAWLIFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AWLIF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AWLIF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AWLIF
Annual income on $10K today (after 15% tax)
$41,463.41/yr
After 10yr DRIP, annual income (after tax)
$30,743,143,852.07/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, AWLIF beats the other by $30,743,122,796.07/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AWLIF + ABBV for your $10,000?

AWLIF: 50%ABBV: 50%
100% ABBV50/50100% AWLIF
Portfolio after 10yr
$25377.00M
Annual income
$18,084,214,651.81/yr
Blended yield
71.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AWLIF
No analyst data
Altman Z
1.4
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AWLIF buys
0
ABBV buys
0
No recent congressional trades found for AWLIF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAWLIFABBV
Forward yield487.80%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$50753.89M$102.3K
Annual income after 10y$36,168,404,531.85$24,771.77
Total dividends collected$49478.61M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AWLIF vs ABBV ($10,000, DRIP)

YearAWLIF PortfolioAWLIF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$59,480$48,780.49$11,550$430.00+$47.9KAWLIF
2$334,811$271,167.03$13,472$627.96+$321.3KAWLIF
3$1,784,770$1,426,522.08$15,906$926.08+$1.77MAWLIF
4$9,016,553$7,106,848.63$19,071$1,382.55+$9.00MAWLIF
5$43,202,271$33,554,559.81$23,302$2,095.81+$43.18MAWLIF
6$196,483,123$150,256,693.49$29,150$3,237.93+$196.45MAWLIF
7$848,895,486$638,658,543.63$37,536$5,121.41+$848.86MAWLIF
8$3,487,095,949$2,578,777,778.75$50,079$8,338.38+$3487.05MAWLIF
9$13,631,297,985$9,900,105,319.66$69,753$14,065.80+$13631.23MAWLIF
10$50,753,893,375$36,168,404,531.85$102,337$24,771.77+$50753.79MAWLIF

AWLIF vs ABBV: Complete Analysis 2026

AWLIFStock

Ameriwest Lithium Inc. engages in the acquisition, exploration, and development of natural resources properties in Canada and the United States. The company focuses on exploring Nevada's Deer Musk East property consists of 283 claims covering an area of 5,500 acres located in the prolific Clayton Valley; the Railroad Valley property comprising 462 claims covering an area of approximately 9,097 acres; the Edwards Creek Valley consists of 1,243 contiguous claims covering an area of 22,200 acres; and the Thompson Valley property covering an area of 2,859 acres located in Yavapai County. Its resource portfolio includes the ESN project located in White Pine County, Nevada; the Koster Dam property located in the Clinton Mining Division of British Columbia; and Quet and Fire property located in Canada. The company was formerly known as Oakley Ventures Inc. and changed its name to Ameriwest Lithium Inc. in April 2021. Ameriwest Lithium Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Full AWLIF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AWLIF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AWLIF vs SCHDAWLIF vs JEPIAWLIF vs OAWLIF vs KOAWLIF vs MAINAWLIF vs JNJAWLIF vs MRKAWLIF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.